Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (AXSM) Stock Overview
Explore Axsome Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
8.6B
P/E Ratio
-46.58
EPS (TTM)
$-3.68
ROE
-2.54%
AXSM Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Axsome Therapeutics, Inc. (AXSM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 54.33, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $170.02.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -46.58 and a market capitalization of 8.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.